Unknown

Dataset Information

0

Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients.


ABSTRACT: Maraviroc treatment for HIV-1 infected patients results in larger CD4(+) T cell rises than are attributable to its antiviral activity alone. We investigated whether this is due to modulation of T cell activation and inflammation.Thirty maraviroc-treated patients from the Maraviroc versus Efavirenz Regimens as Initial Therapy (MERIT) study were randomly selected from among those who had CCR5-tropic (R5) HIV on screening and achieved undetectable HIV RNA (<50 copies/mL) by Week 48. Efavirenz-treated controls were matched for baseline characteristics to the maraviroc-treated patients selected for this substudy. Changes in immune activation and inflammation markers were examined for associations with CD4(+) T cell changes. Maraviroc treatment tended to result in more rapid decreases in CD38 expression on CD4(+) T cells and in plasma D-dimer concentrations than did treatment with efavirenz. The proportion of patients with high-sensitivity C-reactive protein >2 µg/mL increased from 45% to 66% in the efavirenz arm, but remained constant in the maraviroc arm (P?=?0.033). Decreases in CD38 expression on CD8(+) T cells were correlated with CD4(+) T cell rises for maraviroc treatment (r?=?-0.4, P?=?0.048), but not for treatment with efavirenz.Maraviroc-treated patients had earlier, modest decreases in certain markers of immune activation and inflammation, although in this small study, many of the differences were not statistically significant. Levels of high-sensitivity C-reactive protein remained constant in the maraviroc arm and increased in the efavirenz arm. Decreases in immune activation correlated with increased CD4(+) T cell gains.ClinicalTrials.gov NCT00098293.

SUBMITTER: Funderburg N 

PROVIDER: S-EPMC2950842 | biostudies-literature | 2010 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients.

Funderburg Nicholas N   Kalinowska Magdalena M   Eason James J   Goodrich James J   Heera Jayvant J   Mayer Howard H   Rajicic Natasa N   Valdez Hernan H   Lederman Michael M MM  

PloS one 20101006 10


<h4>Background</h4>Maraviroc treatment for HIV-1 infected patients results in larger CD4(+) T cell rises than are attributable to its antiviral activity alone. We investigated whether this is due to modulation of T cell activation and inflammation.<h4>Methods and findings</h4>Thirty maraviroc-treated patients from the Maraviroc versus Efavirenz Regimens as Initial Therapy (MERIT) study were randomly selected from among those who had CCR5-tropic (R5) HIV on screening and achieved undetectable HIV  ...[more]

Similar Datasets

| S-EPMC5700350 | biostudies-literature
2014-04-16 | GSE56804 | GEO
| S-EPMC4614410 | biostudies-literature
| S-EPMC3522814 | biostudies-literature
2014-04-16 | E-GEOD-56804 | biostudies-arrayexpress
| S-EPMC6521995 | biostudies-literature
| S-EPMC3685899 | biostudies-literature
| S-EPMC9400477 | biostudies-literature
| S-EPMC4252101 | biostudies-other
| S-EPMC4729387 | biostudies-literature